EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two‐drug regimen in SWORD‐1/‐2 phase 3 studies

Rashmi Mehta, Chakradhar V Lagishetty, Konstantinos Angelis, Alicia Aylott, Lesley Kahl, Libby Blair, Jessica Matthews, Brian Wynne, Herta Crauwels, Mark Underwood, Kimberly K Adkison

British Journal of Clinical Pharmacology · 2023

DOI: 10.1111/bcp.15683 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2023. Verfasst von Rashmi Mehta und 10 weiteren Autor:innen. Beteiligte Einrichtung: GSK, Durham, North Carolina, USA. Hauptthemen laut MEDLINE: Anti-HIV Agents, HIV Infections. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: ViiV Healthcare, Janssen Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

SWORD‐1 and SWORD‐2 phase 3 studies concluded that switching virologically suppressed participants with HIV‐1 from their current three‐ or four‐drug antiretroviral regimen (CAR) to the two‐drug regimen of once‐daily dolutegravir (DTG, 50 mg) and rilpivirine (RPV, 25 mg) was safe, well tolerated and noninferior for maintaining HIV‐1 suppression at week 48 and highly efficacious to week 148. A secondary objective was to characterize drug exposure and exposure‐efficacy/safety relationships.

Methods

Adults with plasma HIV‐1 RNA

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-HIV AgentsHIV InfectionsAdultHumansMiddle AgedRilpivirineOxazinesPyridonesHeterocyclic Compounds, 3-RingAnti-Retroviral AgentsTreatment OutcomeRNAViral LoadDolutegravir

Stichwörter der Autor:innen

HIV/AIDSpharmacokinetic-pharmacodynamicsystemic pharmacology

Substanzen

Anti-HIV AgentsRilpivirineOxazinesPyridonesHeterocyclic Compounds, 3-RingAnti-Retroviral AgentsRNADolutegravir

Autor:innen und Institutionen

  • GSK, Durham, North Carolina, USA.
  • GSK, Upper Providence, Pennsylvania, USA.
  • GSK, Brentford, UK.
  • GSK, Stevenage, UK.
  • ViiV Healthcare, Brentford, UK.
  • ViiV Healthcare, Durham, North Carolina, USA.

Förderung

  • ViiV Healthcare
  • Janssen Research and Development

Zitieren

APA

Mehta, R., Lagishetty, C. V., Angelis, K., Aylott, A., Kahl, L., Blair, L., Matthews, J., Wynne, B., Crauwels, H., Underwood, M., & Adkison, K. K. (2023). Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two‐drug regimen in SWORD‐1/‐2 phase 3 studies. British Journal of Clinical Pharmacology. https://doi.org/10.1111/bcp.15683

Vancouver

Mehta R, Lagishetty CV, Angelis K, Aylott A, Kahl L, Blair L, et al. Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two‐drug regimen in SWORD‐1/‐2 phase 3 studies. British Journal of Clinical Pharmacology. 2023. doi:10.1111/bcp.15683

BibTeX
@article{Mehta2023,
  author = {Mehta, Rashmi and Lagishetty, Chakradhar V and Angelis, Konstantinos and Aylott, Alicia and Kahl, Lesley and Blair, Libby and Matthews, Jessica and Wynne, Brian and Crauwels, Herta and Underwood, Mark and Adkison, Kimberly K},
  title = {Pharmacokinetic and pharmacokinetic/pharmacodynamic characterization of the dolutegravir/rilpivirine two‐drug regimen in SWORD‐1/‐2 phase 3 studies},
  journal = {British Journal of Clinical Pharmacology},
  year = {2023},
  doi = {10.1111/bcp.15683}
}
Kostenlos starten →